Lung cancer survival in patients with autoimmune disease
Patients with autoimmune disease and lung cancer pose a multidisciplinary treatment challenge, particularly with the advent of immunotherapy.
However, the association between autoimmune disease and lung cancer survival is largely unknown.
The objective of retrospective cohort study between 2003 and 2019 at a single academic medical center ( Northwestern University ) was to determine the association between autoimmune disease and lung cancer survival.
Researchers have identified 349 patients with lung cancer and several autoimmune diseases.
Types of lung cancers included small cell, adenocarcinoma, squamous cell carcinoma, non-small cell not otherwise specified, and large cell carcinoma.
Autoimmune diseases included rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, mixed connective tissue disease, myositis, and Sjögren syndrome.
Inclusion criteria were biopsy-confirmed lung cancer, autoimmune diagnosis confirmed by a rheumatologist, and death or an encounter listed in the electronic medical record within 2 years of study end.
A control group of patients with biopsy-proven lung cancer but without autoimmune disease was identified.
Data analysis was conducted from March to July 2020.
The primary endpoints were overall survival ( OS ) and progression-free survival ( PFS ) in patients with autoimmune disease.
The hypothesis was that patients with autoimmune disease would have worse progression-free survival and overall survival compared with patients in the control group.
Of the original 349 patients, 177 met inclusion criteria. Mean age at lung cancer diagnosis was 67.0 years and 136 ( 76.8% ) were women.
Most common autoimmune diseases were rheumatoid arthritis ( 97 [ 54.8% ] ), systemic sclerosis ( 43 [ 24.3% ] ), and systemic lupus erythematous ( 15 [ 8.5% ] ).
Most common lung cancers were adenocarcinoma ( 99 [ 55.9% ] ), squamous cell carcinoma ( 29 [ 16.4% ] ), and small cell lung cancer ( 17 [ 9.6% ] ).
A total of 219 patients ( mean age at diagnosis, 65.9 years; 173 [ 79.0% ] ) were identified as having lung cancer without autoimmune disease and included in the control cohort.
Compared with patients in the control group, patients with autoimmune disease experienced no difference in overall survival ( log-rank P = 0.69 ).
A total of 126 patients ( 69.5% ) with autoimmune disease received standard of care vs 213 patients ( 97.3% ) in the control group ( P less than 0.001 ).
No individual autoimmune disease was associated with worse prognosis, even among patients with underlying interstitial lung disease.
In conclusion, compared with institutional controls, patients with autoimmune disease experienced no difference in survival despite the fact that fewer patients in this group received standard-of-care treatment.
No individual autoimmune disease was associated with worse prognosis.
Future multicenter prospective trials are needed to further evaluate autoimmune disease and lung cancer survival. ( Xagena )
Jacob S et al. JAMA Netw Open 2020. PMID: 33315114
Keytruda as first-line treatment in adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer, approved by European Commission
The European Commission has approved Keytruda ( Pembrolizumab ), an anti-PD-1 therapy, as a monotherapy for the first-line treatment of...
Keytruda plus Lenvima combination for patients with certain types of advanced endometrial carcinoma - FDA approved
The U.S. Food and Drug Administration ( FDA ) has approved the combination of Keytruda ( Pembrolizumab ), an anti-PD-1...
Ponvory for the treatment of adults with relapsing forms of multiple sclerosis with active disease - Approved in European Union
The European Commission ( EC ) has approved Ponvory ( Ponesimod ) for the treatment of adult patients with relapsing...
Opdivo + Yervoy as the first immunotherapy treatment for previously untreated unresectable malignant pleural mesothelioma, FDA approved
The U.S. Food and Drug Administration ( FDA ) has approved Opdivo ( Nivolumab ) 360 mg every three weeks...
Kesimpta, self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis, FDA approved
The FDA ( US Food and Drug Administration ) has approved Kesimpta ( Ofatumumab, formerly OMB157 ) as an injection...
Newborns face unique immunological challenges immediately after birth. As they depart a relatively sterile fetal environment, they are abruptly exposed...
Keytruda for patients with BCG-unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy, approved by FDA
The FDA ( U.S. Food and Drug Administration ) has approved Keytruda ( Pembrolizumab ), an anti-PD-1 therapy, as monotherapy...
In December 2019, a novel pneumonia caused by a previously unknown pathogen emerged in Wuhan, a city of 11 million...
Opdivo plus Yervoy for patients with hepatocellular carcinoma previously treated with Sorafenib, FDA approved
Opdivo ( Nivolumab ) 1 mg/kg plus Yervoy ( Ipilimumab ) 3 mg/kg ( injections for intravenous use ) was...